Current in vitro approaches for investigational toxicology, drug metabolism (DMPK) and safety are limited.

Furthermore, they are not fully representative of human response; therefore, drugs showing acceptable preclinical toxicity often fail in human clinical trials, and accurately predicting human drug exposure for new compounds is challenging and costly.

Watch this webinar to learn:

• Developing liver-on-chip MPS systems and comparison to traditional in vitro liver approaches
• Modeling human hepatotoxicity prediction using liver-MPS
• Modeling human drug clearance using liver-MPS
• Data validating and translatability between organ-on-chips and human
• Accessing CN Bio MPS technology

Microphysiological Systems (MPS), or Organ-on-chip (OOC) technologies are a trending way to bridge the gap between traditional DMPK/toxicology assays and human trials by providing more robust and reliable data that translate into clinical outcomes.

CN Bio offers preclinical investigational toxicology and DMPK services using its proprietary, industry-proven PhysioMimix® OOC technology and liver-on-a-chip model. In this webinar, we will share our latest advances in investigational toxicology, drug clearance and drug safety, highlighting how the translatable, human-relevant data generated using CN Bio’s liver-on-a-chip model can be used to support (or call into question) the conclusions of internal pre-clinical studies, helping you to make data driven decisions with greater confidence.

View our Q&A document from the live event.

Speaker Information:

Dr Tomasz Kostrzewski

VP – Science & Technology
CN Bio